Polysaccharide Silicic Acid Capsules for Stable Oral Absorption

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing formulations of stabilized silicic acid face challenges in achieving high bioavailability, stability, and patient compliance due to hygroscopicity, acidity, and unpleasant taste, leading to ineffective dosing and absorption issues.

Innovation Solution

A capsule formulation using a polysaccharide or polysaccharide derivative shell filled with an acidic liquid stabilized silicic acid, stabilized with a quaternary ammonium compound, and optionally containing rheological additives, which maintains stability and bioavailability while allowing for smaller capsule sizes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Stability of the object's composition

If orthosilicic acid is stabilized by quaternary ammonium compound, then stability is improved, but taste and odor deteriorate

Engineering Contradiction:

ImprovestabilityVSAvoidtaste and odor

Core Design Contradiction:

Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the stabilizing function from the quaternary ammonium compound itself and transfers it to a polysaccharide-based capsule shell. The stabilizer is taken out from the liquid formulation and embedded in the capsule material, separating the stabilizing function from the harmful taste and odor sources.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The polysaccharide capsule shell acts as an intermediary carrier that provides stabilization without direct contact between the quaternary ammonium compound and the patient's taste buds. The capsule shell mediates between the unstable orthosilicic acid and the patient, eliminating the harmful sensory effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If liquid formulation is used, then bioavailability is improved, but stability deteriorates

Engineering Contradiction:

ImprovebioavailabilityVSAvoidstability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent uses a flexible polysaccharide capsule shell that encapsulates the liquid orthosilicic acid formulation. The shell provides physical protection and chemical stabilization while allowing the liquid core to maintain its bioavailability properties. The thin film structure ensures rapid dissolution upon ingestion.

Inventive Principle:

Principle #30Flexible shells and thin films

3Stability of the object's composition

If solid formulation is used, then stability is improved, but effective silicon concentration deteriorates

Engineering Contradiction:

ImprovestabilityVSAvoideffective silicon concentration

Core Design Contradiction:

Stability of the object's compositionVSQuantity of substance

Solution Approach 1:

The patent segments the formulation into a stable polysaccharide capsule shell and a concentrated liquid core containing orthosilicic acid. This segmentation allows the shell to provide stability while the liquid core maintains high effective silicon concentration, combining advantages of both solid and liquid formulations.

Inventive Principle:

Principle #1Segmentation

4Ease of operation

If capsule size is reduced, then compliance is improved, but carrier material mass deteriorates

Engineering Contradiction:

ImprovecomplianceVSAvoidcarrier material mass

Core Design Contradiction:

Ease of operationVSWeight of stationary object

Solution Approach 1:

The patent changes the physical state parameter of the carrier material from solid particles (requiring large capsule size) to a liquid formulation encapsulated in a thin polysaccharide shell. This parameter change enables small capsule size with minimal carrier material while maintaining stability and bioavailability.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The formulation ensures high stability and bioavailability of silicic acid, enhancing patient compliance and effective absorption, particularly for conditions like bone loss, cartilage degeneration, and skin aging, with improved dosing convenience.

Implementation Method 1

a capsule formulation using a polysaccharide or polysaccharide derivative shell filled with an acidic liquid stabilized silicic acid

Methodology Applied

Scientific EffectPhysical containment: Physical Containment

Implementation Method 2

Orthosilicic acid may be stabilized by means of a stabilizer, suitably chosen from the group of quaternary ammonium compounds and amino acids

Methodology Applied

Scientific EffectStabilization:

Implementation Method 3

the liquid form of concentrated stabilized-OSA that forms the basis for both liquid and solid formulations is acidic, with a pH around 1, so as to prevent polycondensation

Methodology Applied

Scientific EffectAcidic stabilization:

Implementation Method 4

This oligomerisation however does not convert the orthosilicic acid into silica, but rather into oligomers which may be converted (particularly by hydrolysis) to orthosilicic acid in the gastro-intestinal tract

Methodology Applied

Scientific EffectHydrolysis: Hydrolysis

Data Source

PatentUS20260021134A1Silicic acid formulation and use thereof

Publication Date: 2026.01.22 BIO MINERALS

AI summary

The capsule comprises a capsule shell and filled with an acidic liquid formulation comprising stabilized silicic acid, wherein the capsule shell comprises a polysaccharide and/or a polysaccharide derivative. The stabilization may be achieved with a quaternary ammonium compound. The capsule can be part of a capsule-in-capsule product, wherein the outer capsule contains furthermore a composition such as an oil. The capsule may be applied as a dietary supplement or as a medicament.